Every Form 4 that ResMed Inc. (RMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RMD filings page.
ResMed Inc. (RMD) reported insider information for director Richard Sulpizio on a Form 4. Following the reported activity, he beneficially owned 17,796 shares of ResMed common stock in direct ownership. The filing also notes that Sulpizio ceased to serve as a director at the conclusion of ResMed’s 2025 annual meeting of stockholders held on November 19, 2025, marking his departure from the company’s board.
ResMed Inc. director activity: A company director reported option exercises and related share dispositions in ResMed Inc. common stock. On 11/14/2025, the director exercised 11,442 stock options at an exercise price of $101.64 per share, adding 11,442 shares to their direct holdings. On the same date, 7,314 shares were disposed of at $244.46 per share to cover tax withholding and the cost to exercise options originally granted on 11/14/2018. After these transactions, the director directly owned 70,238 shares of ResMed common stock, and the reported option grant covering 11,442 shares was fully exercised, leaving 0 derivative securities from that grant.
ResMed Inc. (RMD) filed a Form 4 reporting a routine insider transaction by director Harjit Gill. On 11/11/2025, 38.209 shares of ResMed common stock were disposed of under transaction code F at a $250.1 price to cover taxes upon vesting of previously granted RSUs. Following this withholding event, Gill beneficially owns 9,867 shares, held directly. The filing notes the RSUs were originally granted on 11/20/2024. This reflects administrative tax withholding rather than an open‑market sale.
ResMed Inc. (RMD) director Mr. Farrell reported two recent stock transactions. On 11/11/2025, he disposed of 162.953 shares of ResMed common stock at $250.10 per share, sent back to the company to cover taxes on the vesting of restricted stock units granted on 11/20/2024. On 11/12/2025, he sold 2,000 shares of ResMed common stock at an average price of $252.05 per share in an open-market transaction. After these actions, he beneficially owns 66,110 shares directly. The sale on 11/12/2025 was made under a Rule 10b5-1 trading plan adopted on August 12, 2025.
ResMed Inc. (RMD) Chairman and CEO Michael Farrell, who is also a director, reported routine share dispositions related to tax withholding on restricted stock unit (RSU) vesting. On 11/11/2025, he disposed of 2,231.545, 3,459.325, and 2,205.697 shares of ResMed common stock back to the issuer at a price of $250.1 per share, each coded "F" to indicate they were withheld for taxes upon RSU vesting from grants dated 11/16/2022, 11/16/2023, and 11/16/2024. After these transactions, Farrell beneficially owned 459,969 ResMed shares directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.
ResMed Inc. director Jan De Witte reported stock transactions in company shares. On 11/11/2025, he sold 487 shares of ResMed common stock at $250.25 per share under a pre-arranged Rule 10b5-1 trading plan adopted on Feb 03, 2025. On the same date, 76.449 shares were disposed of to the issuer to cover tax withholding tied to the vesting of previously granted restricted stock units from 11/20/2024. After these transactions, he directly owned 5,242 shares of ResMed common stock.
ResMed Inc. (RMD) reported an insider transaction by Michael J. Rider, Global General Counsel, on 11/11/2025. The filing shows issuer share withholdings for taxes upon RSU vesting (transaction code F).
Withholdings were 135.075, 173.725, 715.489, and 500.735 shares of common stock at $250.1 per share, tied to RSU grants dated 11/18/2021, 11/16/2022, 11/16/2023, and 11/20/2024. After these transactions, Rider beneficially owned 9,841 shares directly. Holdings include 38.9396 shares acquired on 10/31/2025 through the ResMed Employee Stock Purchase Plan.
ResMed Inc. (RMD) reported insider activity by Chairman and CEO Michael J. Farrell. On 11/07/2025, he exercised stock options at $101.64 for 983 shares and 7,028 shares, and sold 8,011 shares at a weighted average price of $249.7532 (multiple trades between $248.13 and $251.46). The transactions were made pursuant to a Rule 10b5-1 plan adopted October 31, 2024.
Following these transactions, Farrell beneficially owned 467,866 shares directly and 2,090 shares indirectly via the Lisette and Michael Farrell Family Trust. Notes indicate options first became exercisable on 11/11/2019 and vest one-third per year, with expiration on 11/14/2025, and that holdings include 74.3412 shares purchased through the Employee Stock Purchase Plan on October 31, 2025.
ResMed (RMD) reported a Form 4 for CFO Brett Sandercock. On 11/03/2025, he exercised 2,000 stock options at $101.64 (code M) and sold 3,000 shares at $247.54 (code S). Following these transactions, he directly beneficially owns 85,745 shares. The activity was conducted under a Rule 10b5-1 plan adopted on February 19, 2025. The exercised options were from a grant first exercisable on 11/11/2019 and vest 1/3 per year, expiring 11/14/2025.